logo
H5N1 bird flu virus is stable and infectious in raw milk cheese for months, study shows

H5N1 bird flu virus is stable and infectious in raw milk cheese for months, study shows

CNN14-03-2025
Raw cheese made with milk from dairy cattle infected with bird flu can harbor infectious virus for months and may be a risk to public health, according to a new study from researchers at Cornell University that was funded by the US Food and Drug Administration.
Raw milk cheeses are those made with milk that hasn't been heat-treated, or pasteurized, to kill germs.
Although federal law prohibits the sale of raw milk across state lines, sales of raw milk cheese are legal nationwide as long as it's aged at least 60 days before landing on store shelves. This requirement, which has been in place since 1949, is thought to cut the risk of contamination, since it allows development of natural acids and enzymes, which were believed to kill off pathogens.
The new study shows that this aging process may not inactivate the H5N1 virus, however, and it underscores the risk of consuming raw or undercooked foods during the bird flu outbreak, which continues to infect dairy cattle, poultry and a growing number of other animal species.
The same group of researchers previously found that H5N1 virus remained infectious in refrigerated raw milk for up to eight weeks.
Dr. Diego Diel, who led the study, says he thinks the virus may be so stable in milk and cheese because it's protected by the complex matrix of molecules around it.
'The protein and fat content in the cheese and milk provide a good environment for the virus to survive at refrigeration temperature,' said Diel, an associate professor of virology at Cornell.
Robert F. Kennedy Jr., secretary of the US Department of Health and Human Services, has said food doesn't pose a bird flu risk.
'The disease is not passed through food, so you cannot get it – as far as we know, you cannot get it from an egg or milk or meat from an infected animal,' Kennedy told Fox News in an interview that aired Tuesday.
But that's only partly true. Cats and other animals have been infected by raw cow's milk and raw pet food, and there have been at least three confirmed human infections in which investigators were unable to determine the source of the person's exposure to the H5N1 virus.
There have been no confirmed reports of people getting sick from eating or drinking bird-flu contaminated foods, including raw milk cheese, but dairy workers have been infected by getting splashed with raw milk in their faces or eyes.
It's still not entirely clear whether humans can be infected by eating or drinking contaminated food, Diel said, noting that his study wasn't really designed to answer that question.
'I do think it is possible. There is a risk of infection,' he said. 'It obviously depends on the dose, how much of that contaminated product is ingested.'
It may also depend on the strain of virus in the milk or cheese. Diel and his team tested the stability of the B3.13 virus, which originally infected cattle in the US in March 2024. B3.13 has caused only mild disease in people. However, a new strain, D1.1, which has been associated with some severe human cases, has also crossed into cattle, further increasing the risk.
For the study, the researchers made mini cheeses with milk they spiked with H5N1 virus. They made these cheeses at three pH levels: 6.6, 5.8 and the most acidic formula, 5.0.
The researchers then tested the cheeses over time to see whether any virus capable of infecting cells remained. They injected samples into fertilized chicken eggs, considered the gold standard test.
Levels of the virus remained high for the first seven days after the cheese was made and then dropped a bit in the cheeses produced at pH levels 6.6 and 5.8. But importantly, the virus remained infectious for the full two-month aging period, showing that it was remarkably stable in the cheese over a long period.
Those results were confirmed by some real-world examples. The researchers tested samples of raw milk cheese from a farm that had inadvertently produced them with milk from cows infected with bird flu. These findings also showed that levels of virus stayed high and remained infectious over the full two months of aging.
'Our study demonstrates that HPAI H5N1 virus exhibits remarkable stability throughout the cheese making process,' the authors wrote in their preprint study, posted ahead of peer review Friday.
However, the study suggested that making raw milk cheese more acidic may kill the virus and make the cheese safer to eat. No live virus was detected in the cheese produced at the lowest pH, 5.0. Prior studies have also shown that common pasteurization methods inactivate the virus.
Experts said the new study was consistent with tests of the stability of the virus in milk.
'We have also observed that milk can change the pH needed to inactivate the virus,' said Dr. Seema Lakdawala, an associate professor of microbiology and immunology at Emory University, who has been studying the transmission of H5N1.
'We and others have repeatedly observed that milk will prevent the degradation of the virus on surfaces, and it increases the pH stability, such that a much lower pH than normal is needed to inactivate the virus,' said Lakdawala, who was not involved in the new study.
The FDA posted the findings of the study Friday along with preliminary results from its own ongoing sampling study of raw cheese.
The FDA sampling study, which was announced in December, has tested 110 cheese samples taken from store shelves across the country. So far, 96 of those samples were negative by polymerase chain reaction testing, or PCR, which detects live virus as well as inactive viral particles, indicating that those cheeses probably weren't made with contaminated milk. The results from the remaining 14 samples are pending, the agency said.
'The FDA is continuing to work with Federal and state partners to address the ongoing outbreak of HPAI A (H5N1) in dairy cattle. The FDA has sampled a total of 464 pasteurized dairy products, including milk cheese butter and ice cream, all were negative for viable H5N1. In addition, multiple research studies have confirmed that pasteurization inactivates the virus,' the statement said.
Still, experts say the study is a good reminder of the importance of surveillance – and of not consuming raw milk products.
'This is another reason we should push to ensure there is no bird flu in milk products and only consume pasteurized dairy products,' Lakdawala said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA grants de novo authorisation to Artera's prostate software
FDA grants de novo authorisation to Artera's prostate software

Yahoo

time11 hours ago

  • Yahoo

FDA grants de novo authorisation to Artera's prostate software

The US Food and Drug Administration (FDA) has granted de novo authorisation to Artera's ArteraAI Prostate software. This marks it as an inaugural AI-powered software with the ability to predict long-term results for those with non-metastatic prostate cancer. This regulatory milestone categorises ArteraAI Prostate as a software as a medical device (SaMD) and enables the use of such AI-assisted tools in qualified pathology laboratories across the US. The authorisation also sets a new product code for similar future digital pathology risk-stratification applications. The FDA's decision includes a Predetermined Change Control Plan that allows the company to widen its platform by validating compatibility with more digital pathology scanners with no need for additional 510(k) submissions. The test was previously granted a breakthrough device designation by the US regulator. Artera's broader multimodal artificial intelligence (MMAI) platform is already on the market through ArteraAI as a laboratory-developed test (LDT). The MMAI biomarker test of the company utilises an algorithm that evaluates digital biopsy images and clinical data to forecast the efficacy of hormone therapy and estimate long-term patient outcomes. This algorithm is the product of extensive development, drawing from vast datasets, including various patients and pathology slides, and has been clinically validated through several Phase III randomised studies. Artera's portfolio also includes other MMAI-powered products such as the ArteraAI Prostate Biopsy Assay, ArteraAI Prostate, and ArteraAI Breast Test. Artera co-founder and CEO Andre Esteva said: 'The FDA's decision validates the power of our MMAI platform to deliver on our vision to create AI-guided tools that enable data-backed and tailored treatments for each patient, leading to more confidence throughout the cancer journey, and ultimately, save more lives.' In February 2025, Artera announced a partnership with Tempus to broaden the availability of the AI-based prostate cancer test. "FDA grants de novo authorisation to Artera's prostate software" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Alzheimer's disease market to reach $17bn across 8MM by 2033
Alzheimer's disease market to reach $17bn across 8MM by 2033

Yahoo

timea day ago

  • Yahoo

Alzheimer's disease market to reach $17bn across 8MM by 2033

The Alzheimer's disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033 across the eight major markets (8MM: the China, France, Germany, Japan, Italy, Spain, the UK and the US), according to GlobalData's recent report, Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update. The major driving factors of this growth include the ageing global population, which will lead to an increase in prevalent cases, the entry of expensive disease-modifying therapies (DMTs) into the market, which will likely result in increased treatment rates as more options become available, and the launch of novel symptomatic therapies including the first US Food and Drug Administration (FDA)-approved therapies for the treatment of agitation and psychosis associated with Alzheimer's. A major focus of research and development in the Alzheimer's therapeutic space is preventing the accumulation of amyloid beta (Aβ). Despite many historical failures, this strategy has come to fruition for drug developers in recent years with the entry of the first DMTs to the market. The FDA approved Eisai/Biogen's Leqembi (lecanemab) in January 2023 and Lilly's Kisunla (donanemab) in July 2024, and both drugs have since been approved in Japan, China and the UK. In April 2025, after multiple delays, the European Medicines Agency approved Leqembi in a restricted population compared with the US, preventing it from being prescribed to patients who are APOE4 homozygotes [individuals who have inherited two copies of the APOE4 gene variant, one from each parent, increasing their likelihood of developing the disease]. Although the approval of the first DMTs for the treatment of Alzheimer's is a significant step forward, a key limiting factor in their uptake has been their integration into clinical practice so that they can be widely available for patients. Frequent intravenous (IV) administration places a high burden on care settings in which the drug can be administered, and access to positron emission tomography and magnetic resonance imaging (MRI) scans is a key economic and operational limiting factor for access to these drugs. In addition to logistical factors, these new DMTs are significantly more expensive than the current highly genericised symptomatic treatments used in the management of Alzheimer's, providing a further access challenge in the form of reimbursement/payer restrictions. Indeed, the Japanese Central Social Insurance Medical Council (Chuikyo) recently approved the cost-effectiveness assessment results for Leqembi, recommending a 15% price reduction, with the price change expected to come into effect from 1 November 2025. The final reimbursement guidance for Leqembi and Kisunla in the UK, published in June 2025 following two previous rejections, is that neither drug is recommended for use on the NHS. Developers are investigating alternative routes of administration so that patients will not require multiple lengthy IV infusions to be treated. Eisai and Biogen are currently evaluating a subcutaneous formulation of Leqembi, and Eli Lilly is developing a second anti-Aβ monoclonal antibody (mAb), remternetug, which can also be administered subcutaneously. Additionally, there are several oral late-stage pipeline products with a variety of mechanisms of action that, if approved, should be easier to integrate into clinical practice and therefore be more widely accessible for patients. In clinical trials, these oral products have not been associated with amyloid-related imaging abnormalities, the key side effect associated with the anti-Aβ mAbs that requires MRI monitoring, which would further improve access to these drugs. Overall, DMTs are expected to dominate the global Alzheimer's market, contributing 69.2% of the market by 2033, with drugs targeting Aβ making up the majority of this. GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $2.9 billion and $2.3 billion, respectively, by 2033. While the market is projected to experience strong growth throughout the forecast period across the 8MM, unmet needs beyond access to treatment will remain. The rates of diagnosis and treatment are low across all stages of the disease, so there is an unmet need for accurate, easy-to-use diagnostic tests, and for biomarkers that can be used for patient classification and the assessment of treatment response. While blood-based biomarkers are now being used fairly routinely in clinical trials and research, they have not yet entered routine clinical practice, although advances are being made with the first FDA approval of a blood test for diagnosis, Fujirebio's Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio, in May 2025. Additionally, the new DMTs are only considered to be moderately effective, so a significant opportunity remains for more effective DMTs that do not just slow progression but also stop the disease, with prevention the end goal. Beyond DMTs, drugs that can effectively improve cognition in the late stages of disease, as well as more effective options for secondary symptoms such as agitation and psychosis, also provide an opportunity for developers. Key opinion leaders interviewed by GlobalData did not believe there will ever be one product that could cure Alzheimer's. Rather, they consistently noted that the future of treatment will entail the combinatory use of preventative, symptomatic and disease-modifying products. Despite the significant anticipated growth of the market, activity remains high and there will be many opportunities for developers. "Alzheimer's disease market to reach $17bn across 8MM by 2033" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Her 6-Year-Old Son Told Her He Wanted to Die. So She Built an AI Company to Save Him
Her 6-Year-Old Son Told Her He Wanted to Die. So She Built an AI Company to Save Him

Gizmodo

timea day ago

  • Gizmodo

Her 6-Year-Old Son Told Her He Wanted to Die. So She Built an AI Company to Save Him

The burgeoning world of AI-powered mental health support is a minefield. From chatbots giving dangerously incorrect medical advice to AI companions encouraging self-harm, the headlines are filled with cautionary tales. High-profile apps like and Replika have faced backlash for harmful and inappropriate responses, and academic studies have raised alarms. Two recent studies from Stanford University and Cornell University found that AI chatbots often stigmatize conditions such as alcohol dependence and schizophrenia, respond 'inappropriately' to certain common and 'encourage clients' delusional thinking.' They warned about the risk of over-reliance on AI without human oversight. But against that backdrop, Hafeezah Muhammad, a Black woman, is building something different. And she's doing it for reasons that are painfully personal. 'In October of 2020, my son, who was six, came to me and told me that he wanted to kill himself,' she recounts, her voice still carrying the weight of that moment. 'My heart broke. I didn't see it coming.' At the time, she was an executive at a national mental health company, someone who knew the system inside and out. Yet, she still couldn't get her son, who has a disability and is on Medicaid, into care. 'Only 30% or less of providers even accept Medicaid,' she explains. 'More than 50% of kids in the U.S. now come from multicultural households, and there weren't solutions for us.' She says she was terrified, embarrassed and worried about the stigma of a child struggling. So she built the thing she couldn't find. Today, Muhammad is the founder and CEO of Backpack Healthcare, a Maryland-based provider that has served more than 4,000 pediatric patients, most of them on Medicaid. It's a company staking its future the radical idea that technology can support mental health without replacing the human touch. On paper, Backpack sounds like many other telehealth startups. In reality, its approach to AI is deliberately pragmatic, focusing on 'boring' but impactful applications that empower human therapists. An algorithm pairs kids with the best possible therapist on the first try (91% of patients stick with their first match). AI also drafts treatment plans and session notes, giving clinicians back hours they used to lose to paperwork. 'Our providers were spending more than 20 hours a week on administrative tasks,' Muhammad explains. 'But they are the editors.' This human-in-the-loop approach is central to Backpack's philosophy. The most critical differentiator for Backpack lies in its robust ethical guardrails. Its 24/7 AI care companion is represented by 'Zipp,' a friendly cartoon character. It's a deliberate choice to avoid the dangerous 'illusion of empathy' seen in other chatbots. 'We wanted to make it clear this is a tool, not a human,' Muhammad says. Investor Nans Rivat of Pace Healthcare Capital calls this the trap of 'LLM empathy,' where users 'forget that you're talking to a tool at the end of the day.' He points to cases like where a lack of these guardrails led to 'tragic' outcomes. Muhammad is also adamant about data privacy. She explains that individual patient data is never shared without explicit, signed consent. However, the company does use aggregated, anonymized data to report on trends, like how quickly a group of patients was scheduled for care, to its partners. More importantly, Backpack uses its internal data to improve clinical outcomes. By tracking metrics like anxiety or depression levels, the system can flag a patient who might need a higher level of care, ensuring the technology serves to get kids better, faster. Crucially, Backpack's system also includes an immediate crisis detection protocol. If a child types a phrase indicating suicidal ideation, the chatbot instantly replies with crisis hotline numbers and instructions to call 911. Simultaneously, an 'immediate distress message' is sent to Backpack's human crisis response team, who reach out directly to the family. 'We're not trying to replace a therapist,' Rivat says. 'We're adding a tool that didn't exist before, with safety built in.' Beyond its ethical tech, Backpack is also tackling the national therapist shortage. In many cases, therapists, unlike doctors, traditionally have to pay out of pocket for the expensive supervision hours required to get licensed. To combat this, Backpack launched its own two-year, paid residency program that covers those costs, creating a pipeline of dedicated, well-trained therapists. More than 500 people apply each year, and the program boasts an impressive 75% retention rate. In 2021, then-U.S. Surgeon General Dr. Vivek H. Murthy has called mental health 'the defining public health issue of our time' while referring at the time to the mental health crisis plaguing young people. Muhammad doesn't dodge the criticism that AI could make things worse. 'Either someone else will build this tech without the right guardrails, or I can, as a mom, make sure it's done right,' she says. Her son is now 11, thriving, and serves as Backpack's 'Chief Child Innovator.' 'If we do our job right, they don't need us forever,' Muhammad says. 'We give them the tools now, so they grow into resilient adults. It's like teaching them to ride a bike. You learn it once, and it becomes part of who you are.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store